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The Role of Structure in the Disposition of
Halogenated Aromatic Xenobiotics
by Linda S. Birnbaum*
Halogenated aromatic xenobiotics such as the chlorinated and brominated biphenyls, naphthalenes, di-
benzodioxins, and dibenzofurans are widespread environmental contaminants. The number, position, and
nature ofthe halogen atoms aswell as the structure ofthe aromatic rings influence the disposition ofthese
chemicals in living systems. Absorption isgovernedprimarily bythe physical properties oflipophilicity and
solubility. Distribution through the blood occurs by nonspecific binding to plasma proteins and cellular
components. Liverand adipose tissue are the major depots. Metabolism is a prerequisite forexcretion. The
highly substituted isomers tend to be resistant to metabolism. The route ofexcretion shifts from urine to
feces with increasing size and number ofhalogen atoms. Although pharmacokinetic modeling has allowed
some predictions to be made from one compound to another or across species, more information on metab-
olism is required in order to improve the ability to predict the disposition in humans ofthis class oftoxic
environmental pollutants.
Halogenated aromatic hydrocarbons constitute a broad
class ofcompounds with varying structure, uses, envi-
ronmental occurrence, and toxicity. The nature of the
halogen atoms(s) involved and the structure ofthe aro-
matic ring(s) deternines the physical properties ofthese
molecules as well as influencing the response ofbiologi-
cal systems to them. The availability of these com-
pounds to their biological target site is governed by a
complex interaction ofphysicalandbiologicalfactors. In
this paper, the structure ofhalogenated aromatic hy-
drocarbons will be correlated with their disposition in
livingsystems. Since extensive reviews have beenwrit-
tenonthe lesscomplex compounds, such asthehalogen-
ated benzenes, onlythemultiring structures such asthe
halogenatednaphthalenes, biphenyls, dibenzodioxins,
and dibenzofurans willbeconsidered. Severalrecentre-
views have concerned the pharmacokinetics ofpolyhal-
ogenated aromatic hydrocarbons (1-4); 2,3,7,8-
tetrachlorodibenzofuran (TCDF) (5); 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin (TCDD) (6,7); and a comparison of
dioxins and furans (8). I shall attempt to emphasize the
similarities and differences in the disposition ofthese
compounds as well as discuss the results of some cur-
rent investigations both in ourlaboratory and others.
There are 75 possible chlorinated dibenzodioxins and
135chlorinated dibenzofuran isomers. Thetotalnumber
ofchlorinated biphenyl and naphthalene isomers is in the
hundreds. Most oftheseisomers exist in complexindus-
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trial mixtures and others have been detected in the en-
vironment due both to industrial contamination and to
breakdown, rearrangement, and pyrolysis ofother hal-
ogenated compounds. A wide variety ofbrominated bi-
phenyls have also beenmade forindustrial purposes but
they are less widespread in the environment. Likewise,
brominated dioxins, furans, and naphthalenes are rare,
although brominated naphthalenes have been shown to
exist as toxic impurities in polybrominated biphenyls
(PBBs) (9). Iodinated and fluorinated biphenyls and
dioxins have been synthesized for pharmaceutical and
research purposes (10,11) but have not been detected as
environmental pollutants.
An analysis of the effect of structure on the disposi-
tion ofthese compounds can be divided into the areas of
absorption, distribution, metabolism and excretion.
Certaingeneralpatternsexistinthedispositionofthese
compounds, but these are modulated by both the ring
structure and the halogen atoms, varying with type,
number, and position.
Absorption into blood is the first step which must oc-
cur for a compound to be able to reach its site ofaction
other than direct local effects, for example, on skin. All
ofthe halogenated dioxins, furans, biphenyls, and naph-
thalenes are uncharged, nonpolar, lipophilic compounds
whose absorption occurs by diffusion across the semi-
permeable membranes ofthe body. Ingeneral, the abil-
ity of a compound to diffuse across membranes is related
to its solubility in the membrane or its hydrophobicity,
a property commonly approximated by measuring a
partition coefficient between an organic and aqueous
solvent. The partition coefficients determined betweenL. S. BIRNBAUM
Table 1. Partition coefficients of representative aromatics.
Compound
Benzene
Fluorobenzene
Chlorobenzene
Bromobenzene
Iodobenzene
Dichlorobenzene
Naphthalene
Log pa
2.13
2.27
2.84
2.99
3.25
3.38
3.37
Biphenyl
4-Chlorobiphenyl
2-Chlorobiphenyl
3-Chlorobiphenyl
6-Chlorobiphenyl
2,2'-Dichlorobiphenyl
4,4'-Dichlorobiphenyl
2,3,2',3'-Tetrachlorobiphenyl
2,3,5,6-Tetrachlorobiphenyl
3,4,3',4'-Tetrachlorobiphenyl
3,5,3',5'-Tetrachlorobiphenyl
2,4,5,2',5'-Pentachlorobiphenyl
2,4,5,2',4',5'-Hexachlorobiphenyl
3,5-Dibromobiphenyl
3,5,4'-Tribromobiphenyl
3,5,3',5'-Tetrabromobiphenyl
Dibenzofuran
4.07
4.26
4.54
4.95
5.08
5.58; 5.18
4.04
4.63
5.46
6.04
6.85
6.11
6.72
5.78
6.41
7.41
4.12
Reference
(12)
(12)
(12)
(12)
(12)
(12)
(12)
(13)
(14)
(15)
(15)
(15)
(12,14)
(14)
(14)
(14)
(14)
(14)
(12)
(12)
2,3,7,8-Tetrachlorodibenzodioxin 5.38 (16)
ap = partition coefficient (n-octanollwater); log p is taken directly
or calculated from cited reference.
n-octane and water are given for a number ofaromatic
hydrocarbons in Table 1. It is clear that lipid solubility,
which is reflected by an increased solubility in octanol,
increases as the ring complexity increases and as the size
and number ofthe halogen atoms vary. Thus, naphthal-
ene is less soluble in water than benzene, while diben-
zofuran is much more lipophilic than naphthalene.
Iodobenzene is less water-soluble thanfluorobenzene,
and dichlorobenzene is more lipophilic than monochlo-
robenzene. Likewise, tetrabromobiphenyl is relatively
more soluble in n-octanol than is tetrachlorobiphenyl. It
is interesting that TCDD has a partition coefficient in the
range ofthe tetrachlorobiphenyls. However, because of
the extremely limited solubility of the highly halogen-
ated aromatics in water, the partition coefficients may
be underestimated. Also, many of the partition coeffi-
cients in the literature are calculated from solubility data
and not actually measured, which may impart some er-
ror (15).
Absorption across the body surfaces is primarily gov-
erned by lipid solubility. However, for compounds with
extremely high partition coefficients (i.e., >7), absorp-
tion into the blood tends to be less than expected. This
may reflect either the extreme insolubility in the aqueous
milieu of the body fluids, since chemicals must be in
solution in order to be absorbed-particulates can only
be taken up by endocytic means which seem to play
little role in the absorption of xenobiotics-or because
they are so lipid-soluble that they become essentially
T!able 2. Relative absorption after oral exposure.
Relative
Compound absorption Reference
4-Chlorobiphenyl + + + + (17)
4,4'-Dichlorobiphenyl + + + + (17)
2,4,5,2',5'-Pentachlorobiphenyl + + + + (17)
2,4,5,2',4',5'-Hexachlorobiphenyl + + + + (17)
2,4,5,2',4',5'-Hexabromobiphenyl + + + + (18)
2,3,7,8-Tetrachlorodibenzofuran + + + + (19-21)
1,2,4,6,8,9-Hexachlorodibenzofuran + + Birnbaum,
unpublished
2,3,7,8-Tetrachlorodibenzodioxin + + + (7)
1,2,3,4,6,7,8,9-Octachlorodibenzo-p-
dioxin + (22)
1,2-Dichloronaphthalene + + + + (23)
1,2,3,4,6,7-Hexabromonaphthalene + + (24)
trapped in the lipid bilayer of cellular membranes in-
stead ofcontinuing to cross from one side to the other.
The extent of absorption of several halogenated aro-
matics is given inTable 2. While allthe less halogenated
compounds seem to be completely absorbed, absorption
tendsto decrease withincreasinghalogenation (25). The
relative lackoftoxicity ofcompounds such asoctachloro-
dibenzodioxin (22) may in part be due to its low extent
ofabsorption. Ofcourse, absorption can alsobe strongly
influenced by the vehicle in which the compound is ad-
ministered. Poiger and Schlatter (26) reported that the
presence of dirt or charcoal significantly reduced the
oral absorption of TCDD. TCDD in vaseline was less
absorbed dermallythanifitwere inpolyethylene glycol.
These results are supported by a recent study by
McConnell and co-workers (27) which has shown that
three to five times higher levels of TCDD are needed
to cause toxic effects in guinea pigs when the animals
are treated orally with TCDD mixed with dirt as com-
pared to TCDD in corn oil. In contrast, no differences
in oral absorption were detected when hexabromonaph-
thalene was given in corn oil or in a mixture of Emul-
phor:ethanol:water (1:1:2) (24). Emulphor EL-620 is a
polyethoxylated vegetable oil (GAF Corp., New York,
NY) that has been used successfully in solubilizing highly
lipophilic compounds.
Once a compound is absorbed, its distribution
throughout the body is governed by its transport in the
blood and its ability to diffuse through the membranes
between the blood vessels and the tissues. Transport
through the blood may involve only the free chemical.
However, inthe majority ofcases, and especially where
such lipophilic compounds as the halogenated aromatics
areconcerned, transportinvolves adsorption ofthe com-
pounds to components in the blood, both in whole blood
and in plasma. This binding was first suggested by the
difficulty observed in extracting the highly lipophilic
2,4,5,2',5'-pentachlorobiphenyl from blood, which is a
hydrophilic medium, into organic solvents (28). Asso-
ciation of other chlorinated hydrocarbons having low
water solubility, such as halogenated insecticides, has
been observed with erythrocytes, albumin, and various
other plasma proteins (29). Lipoproteins, in particular,
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are involved in the transport of such hydrophobic mol-
ecules. The binding of such compounds by plasma pro-
teins was found to be nonspecific. Becker and Gamble
(30) reported that both albumin and low-density lipo-
protein bind 2,4,5,2',4',5'-hexachlorobiphenyl effec-
tively in vitro. They suggested that the binding ofvarious
polychlorinated biphenyl (PCB) isomers will depend on
three properties of the chemicals: hydrophobicity, ar-
omaticity, and steric configuration. Maliwaland Guthrie
(31) reported that both 2,4,5,2',4',5'-hexachlorobi-
phenyland3-chlorobiphenyl were rapidly bound invitro
by albumin and by all three classes (high density, low
density, and very low density) oflipoproteins. The bound
hydrocarbons rapidly exchanged between the different
protein classes. However, at equilibrium, the low-den-
sity lipoprotein fraction contained at least half of the
halogenated aromatic compound, while the very low-
density fraction accounted for less than 15%. The rapid
transfer between lipoproteins may help explain the rapid
uptake ofhalogenated aromatic hydrocarbons from blood
by the tissues. Vomachka and co-workers (32) have re-
centlyshownthat gammaglobulin canalso competewith
lipoproteins and albumin for binding 2,4,5,2',4',5'-
hexachlorobiphenyl.
Matthews et al. (29) examined the binding of a series
ofhalogenated biphenyls to blood proteins both in vivo
and in vitro. They observed that as the degree of hal-
ogenation increased, not only did lipid solubility in-
crease as expected from the partition coefficients, but
the binding to lipoproteins also increased. Thus, while
only 30% of biphenyl bound to the lipoprotein fraction
in vitro, 40% of 4-chlorobiphenyl, 50% of 4,4'-dichlo-
robiphenyl, 60% of2,4,5,2',5'-pentachlorobiphenyl, and
80% of both 2,4,5,2',4',5'-hexachloro- and hexabromo-
biphenyls partitioned into the lipoprotein fraction. The
opposite situation existed with the binding to cellular
components of the blood, but factors other than lipid
solubility also seemedinvolved. Thus, transport ofhalo-
genated aromatics in the blood seems to occur by a
partitioning processinto variouslipid-rich phasesrather
than by specific binding. The compounds can then par-
tition from blood components into cellular membranes
thus accounting for the rapid transfer observed in vivo
from blood to tissues.
Given the highly lipophilic nature ofthe halogenated
aromatic compounds, it is not surprising that their
transfer from mother to fetus or from nursing mother
to the neonate reflects their partitioning into lipid-rich
phases. Very low levels of TCDD are actually passed
across the placenta from mother to fetus (33). In fact,
fetal levels of dioxin are at least 100-fold lower than
levels found in the maternal liver. Studies in our labo-
ratory (Birnbaum and Weber, unpublished observa-
tions) have shown that less than 0.1% of the total dose
of either TCDD or TCDF appeared in the fetuses one
day after acute exposure on day 11 of gestation.
Nagayama and co-workers (34) reported that less than
1% of the total amount of a dietary mixture of poly-
chlorinated dibenzofurans ingested by dams was trans-
ferred to the fetuses. However, transfer of the
compounds through the milk was extensive, a situation
previously reported for PCBs (35). The more highly
chlorinated PCBs, such as 2,4,5,2',4',5'-hexachloro-
biphenyl, 2,3,4,2',4',5'-hexachlorobiphenyl and 2,3,4,5,
2',3',4',5'-octachlorobiphenyl, were more transferable
to the offspring through the milk than were the lower
chlorinated congeners, 2,4,4'-tri-, 2,5',3',4'-tetra-, and
2,4,5,2',5'-pentachlorobiphenyl.
After absorption, the halogenated aromatic com-
pounds are rapidly distributed throughout the bodyinto
various tissues. For example, over 90% of an intrave-
nous dose of 2,4,5,2',5'-pentachlorobiphenyl moved from
the blood into the tissues within 10 min after treatment
(28). In general, there seems to be little preferential
deposition in most tissues. A high percentage of the
dose is frequently found in muscle at early time points
after injection due to the large volume of this tissue.
high initial concentrations are observed in highly per-
fused tissues such as the adrenal glands (19). The pri-
marytissue deposits, however, areliver, adiposetissue,
and skin. Brandt (36) also observed concentration of
specific PCB isomers in the lungs.
There is an interesting correlation between structure
and liver/adipose tissue content as seen in Table 3. All
the chlorinated biphenyls and hexabromobiphenyl show
low levels in liverrelative to that seen in adipose tissue.
However, the dioxins, furans, and naphthalenes con-
centrate more in liver than in fat. There also seems to
be a tendency for higher levels ofhalogenation in these
compounds to result in higher liver concentrations. The
values given in Table 3 are all taken from studies on
the rat. Liver/adipose ratios for dichlorobiphenyl are
similar in monkeys and dogs (39), as are the values in
mice forTCDF (20). However, therelativeliver/adipose
tissue levels of TCDD (40) or TCDF (21) in the guinea
pig are lower than in the rat. Hamsters also have lower
liver TCDD levels (41).
The affinity of these compounds for adipose tissue is
most clearly shown in a series of studies in which the
distribution of various halogenated aromatic hydrocar-
Table 3. Relative liver and adipose tissue constants in the rat.
Liver/adipose
Compound (% TD) Reference
4-Chlorobiphenyl 0.16 (17)
4,4'-Dichlorobiphenyl 0.12 (17)
2,4,5,2',5'-Pentachlorobiphenyl 0.12 (17)
2,4,5,2',4',5'-Hexachlorobiphenyl 0.17 (17)
2,3,6,2',3',6'-Hexachlorobiphenyl 0.05 (37)
2,4,6,2',4',6'-Hexachlorobiphenyl 0.11 (37)
2,3,5,2',3',5'-Hexachlorobiphenyl 0.16 (37)
4-Iodobiphenyl 0.08 (11)
2,4,5,2',5'-Hexabromobiphenyl 0.43 (18)
2,3,7,8-TCDD 6.22 (38)
2,3,7,8-TCDF 1.30 (19)
1,2,4,6,7,9-Hexachlorodibenzofuran 1.82 Birnbaum,
unpublished
1,2-Dichloronaphthalene 1.50 (23)
1,2,3,4,6,7-Hexabromonaphthalene 2.51 (24)
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bons varied with the body composition of the animals
in question. In 1981, this laboratory (20) reported that
2,3,7,8-tetrachlorodibenzofuran persisted twice as long
in DBA/2J (D2) mice as in C57BL/6J (B6) mice. By
measuring the levels ofdissectable fat, it was observed
that the D2 mice had approximately 60% more adipose
tissue than the B6 mice. It was suggested that this
higher adipose tissue content might serve as a protec-
tive reservoir for the animal, i.e., while TCDF is in the
fat it cannot execute its toxic effects. This difference in
body composition could in part explain the differential
sensitivity that these two strains of mice exhibit to-
wards this class of halogenated polyaromatic com-
pounds. These results were extended and confirmed by
Gasiewicz et al. (42), who studied the distribution of
TCDD in B6, D2, and B6d2F1 hybrid mice. As was true
for TCDF, more of the dose of TCDD was present in
the adipose tissue and persisted for twice as long in the
"fat" D2 as opposed tothe "lean" B6 orB6D2F1 hybrid.
They observed that the D2 mice possessed approxi-
mately 90% more dissectable adipose tissue than the B6
mice and supported the hypothesis that the sequestra-
tionoflipophilic compounds likeTCDDinadipose tissue
stores could contribute to the decreased sensitivity of
the D2 relative to the B6 mice.
One of the first reports emphasizing the role of adi-
pose tissue in protection against halogenated hydrocar-
bon toxicity was that of Matthews and Anderson (17),
who observed that starvation of rats which had previ-
ously been acutely exposed to 2,4,5,2',4',5'-hexachlo-
robiphenyl resulted in mobilization ofthe chemical stored
in the fat, resulting in elevation ofblood and liver levels
and an increase in the amount excreted. This obser-
vation was further examined by Wyss et al. (43) who
investigated the distribution and excretion of
2,4,5,2',4',5'-hexachlorobiphenyl inseverelydietaryre-
stricted rats. They concluded that while ingrowingrats
highly lipophilic compounds like 2,4,5,2',4',5'-hexa-
chlorobiphenylappeartobeirreversiblystoredinadipose
tissue, this situation can be reversed by drastic reduc-
tion in volume ofthis depot. The storage role ofadipose
tissue was also reported by Birnbaum (44), who com-
pared the distribution of 2,4,5,2',4',5'-hexachlorobi-
phenyl in senescent rats having large adipose tissue
contents to that previously observed in young growing
rats in the same laboratory (17,37). In the old rats (24
months), the volume ofthe adipose tissue deposits was
so great that the concentration (nmole/g tissue) of the
2,4,5,2',4',5'-hexachlorobiphenyl was less than that ob-
served in young animals who had less total body fat.
The role of adipose tissue content as a modifier in the
distribution and effects of this chemical was recently
examined in the two strains ofmice previously used to
examine the role of adipose tissue in the disposition of
TCDF and TCDD. Ahotupa and Mantyla (45) measured
the total body fat by extracting the entire carcass with
ether. They observed thatthe DBAmice contained 90%
more fat than the B6 mice. Therefore, greater doses of
2,4,5,2',4',5'-hexachlorobiphenyl were required to be
adipose tissue levels as reached after low doses were
administered to the B6 strain. Dietaryrestriction ofthe
DBA mouse reduced its fat content, thus altering its
body composition and resulting in a pattern of
2,4,5,2',4',5'-hexachlorobiphenyl distribution resem-
bling that seen in the B6 mouse.
Although tissue volumes play animportantroleinthe
distribution and biological effects of lipophilic halogen-
ated aromatic compounds, the major factor which con-
trols the elimination phase of the disposition of these
chemicals is their metabolism. The general conclusion
that can be drawn from a large number of studies is
thatmetabolism is aprerequisite forexcretion. Without
metabolism, these chemicals tend to remain seques-
tered in body fat or membranes, or bound to plasma
proteins. Only ifhigh levels offree compound are pres-
ent in the blood, as occurred for 2,4,5,2',4',5'-hexa-
chlorobiphenyl under starvation conditions (17,43), do
appreciable amounts ofthe compound diffuse across the
gut wall and appear unchanged in the feces. Otherwise,
essentially all of the excreted chemical, in either urine
or feces, represents the results of metabolic transfor-
mations ofthe original compound.
There are a number of reviews which cover the me-
tabolism ofaryl halides (46,47). For simple halogenated
benzenes, as well as for the more complex halogenated
biphenyls and chlorinated naphthalenes, oxidative me-
tabolism occurs primarily at the site of two adjacent
unsubstituted carbon atoms via an arene oxide inter-
mediate. However, direct insertion ofa hydroxyl group
(48) has recently been shown to be a major route of
metabolism for 2,5,2',5'-tetrachlorobiphenyl.
The number, position, and types ofhalogen atoms all
play a role in regulating the metabolism ofhalogenated
aromatics. It has been suggested that the metabolism
of aryl fluorides is distinct from that of aryl chlorides,
bromides, and iodides (46). In general, the rate of ox-
idativemetabolismdecreaseswiththeelectronegativity
ofthe halide substitution (Cl<Br<I). However, the rates
ofmetabolism tend to decrease as the number of halo-
gens in the aromatic rings increase because of steric
hindrance (47). Parkinson and Safe (49) compared the
in vitro metabolism of biphenyl and the four 4-halobi-
phenyls (fluoro-, chloro-, bromo-, and iodo-. Theirstudy
showedthathalogenation with anyofthehalogen atoms
shifted the minor route of metabolism from 2- to 3-
hydroxylation, while not changing 4-hydroxylation as
the major oxidative pathway. However, the in vivo bi-
ological response, as measured by the induction of cy-
tochrome P-450 enzymes, varied with fluoro- and
bromobiphenyl behaving like biphenyl as distinct from
iodo-andchlorobiphenylwhichshared commoninducing
properties. The physicochemical properties and elec-
tronic parameters ofthese biphenyls cannot account for
the observed differences in hydroxylation. In vivo me-
tabolism studies of4-iodobiphenyl also showed it to be
oxidized primarily to the 4-hydroxy-4'-iodobiphenyl, a
situation analogous to the metabolism of 4-chlorobi-
phenyl (11).
The importance of halogen position as opposed to
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number was studied by Kato et al. (50), who investi-
gated the in vivo metabolism of four symmetrical hex-
achlorobiphenyl isomers, 2,3,5,2',3',5'-, 2,3,6,2',3',6'-,
2,4,5,2',4',5'- and 2,4,6,2',4',6'-. They observed that
the three isomers without vicinal unsubstituted carbon
atoms were slowly metabolized while 2,3,6,2',3',6'-hex-
achlorobiphenyl was readily metabolized and excreted.
Identification of the metabolites showed that dechlori-
nation, chemical shifts, and direct hydroxyl insertion
occurred in addition to arene oxide formation when there
were adjacent unsubstituted carbon atoms.
Biphenyl metabolism has been studied in a variety of
species, including rats, mice, dogs, monkeys, humans,
fish, and birds (3). The above metabolic rules seem to
hold in general for all species examined. For example,
metabolism of 4-bromo- and 4-chlorobiphenyl in the
chicken resulted in the same products as that observed
in the rat and rabbit (51). The major metabolites of
2,5,4'-trichlorobiphenyl were monohydroxylated deriv-
atives in both the monkey (52) and rat (53). However,
a clear species difference was found between the mon-
key and dog in the metabolism of4,4'-dichlorobiphenyl
(39). The dog tends to resemble the rat (17) in being
more able to metabolize this isomerthanis the monkey.
The reverse relationship is true for the metabolism of
2,4,5,2',4',5'-hexachlorobiphenyl, where the monkey is
more similar to the rat than is the dog (54). In fact, the
dog seems to be the only species so far examined which
can readily metabolize 2,4,5,2',4',5'-hexachlorobi-
phenyl. Recent data from the same laboratory also
showed the lack of metabolism of this PCB isomer by
human liver microsomes (55).
The metabolic rules for the chlorinated biphenyls seem
tohold, ingeneral, forthebrominated biphenyls aswell.
Matthews and Anderson (17) showed that2,4,5,2',4',5'-
hexachlorobiphenyl was metabolized and cleared very
slowly. The same brominated isomer, which is a major
component of Firemaster BP-6 (9), was also shown to
beresistant tometabolism (18). Aftertreatingrats with
Firemaster FF-1, Domino et al. (56) showed that
2,4,5,2',5'-pentabromobiphenyl was cleared more rap-
idly than was 2,4,5,3',4'-pentabromobiphenyl. This dif-
ferential excretion was expected due to the absence
of adjacent unsubstituted carbon atoms in the latter
isomer on one ring and the lack of a free para position
on the other. The hexabromobiphenyl isomer,
2,4,5,2',4',5', was persistent and stored in the adipose
tissue. This study demonstrated that the distribution
of this isomer was independent of the distribution of
other isomers in the mixture, since the kinetic data
observed were in agreement with those previously ob-
tained using the purified isomer (18).
The importance of the position of the halogen atoms
on the aromatic ring may be further emphasized by
examiningthe metabolism ofthe halogenated naphthal-
enes. Takeshita and Yoshida (57) could detect no rela-
tionship between the degree of chlorination and the
extent of tissue retention using a polychlorinated na-
phthalene mixture. Both 1- and 2-chloronaphthalene
were readily metabolized to their corresponding hy-
droxylated metabolites (58). Two dichloronaphthalenes,
1,2- and 1,4-, were hydroxylated via arene oxides to
monohydroxy derivatives, aswasthemorehighlychlor-
inated isomer, 1,2,3,4-tetrachloronaphthalene (59). A
dihydrodiol was also produced from the metabolism of
1,2-dichloronaphthalene (23). Oishi and Oishi (60) stud-
ied the disposition of 1,8- and 2,7-dichloronaphthalenes
and observed that the position of the chlorine atom af-
fected thebiologicalhalf-life, with2,7-dichloronaphthal-
ene being more slowly metabolized than the 1,2-isomer.
No metabolites of 1,2,3,4,5,6-hexachloronaphthalene (59)
or octachloronaphthalene were detected (60).
Comparison ofthe effect ofthe type ofhalogen atom
on metabolism was examined by Ruzo et al. (59), who
compared the metabolism of1,4-dichloronaphthalene to
that of 1,4-dibromonaphthalene. While metabolism of
1,4-dichloronaphthalene resulted only in one major
product, 2,4-dichloronaphthol, two metabolites were
produced from 1,4-dibromonaphthalene, 2,4- and 5,8-
dibromonaphthol. These products were due to direct
hydroxylation ofthe unhalogenated ring as well as hal-
ogen shift accompanying an arene oxide intermediate.
Recent work from this laboratory has looked at the
disposition ofamixture oftwohexabromonaphthalenes,
1,2,3,4,6,7- and 2,3,4,5,6,7- (24). These authors specu-
lated that the former isomer was metabolized and ex-
creted, while the latter was persistent. This hypothesis
has been confirmed by the isolation and identification of
the residual hexabromonaphthalene from the liver 10
days after treatment as 2,3,4,5,6,7-isomer (Birnbaum
and McKinney, unpublished observations). The metab-
olitesproducedfrom 1,2,3,4,6,7-hexabromonaphthalene
have not yet been characterized.
While the preference for metabolism to occur at ad-
jacent unsubstituted carbon atoms seems clear for the
halogenated biphenyls and to a lesser extent for the
naphthalenes, the situation with the polyhalogenated
dibenzodioxins and dibenzofurans is less clear. No stud-
ies have been published on the disposition of any but
the chlorinated isomers of these compounds. This may
reflect the lack of environmental occurrence of bromi-
nated dioxins or furans. Chlorinated dibenzofurans ap-
pear to be more readily metabolized than the
corresponding dioxin isomers (61).
Studies of residue analysis of humans environmen-
tally or occupationally exposed to PCDF orPCDD mix-
tures can help elucidate the structural rules governing
the metabolism and elimination of these classes of hal-
ogenated aromatics. In fact, the basic rule that position
and extent of halogenation determine persistence clearly
holds for humans, as demonstrated for PCB isomer re-
tention in occupationally exposed persons (62). In the
"Yusho" poisoning incident, almost 2000 people con-
sumedrice oilcontaminated withPCBs, polychlorinated
dibenzofurans (PCDFs), and polychlorinated quater-
phenyls (63). The degree oftoxicity correlated with the
furan content, ratherthanthe PCB levels. Themajority
of the PCBs and PCDFs in the oil were highly chlori-
nated isomers which would tend to accumulate (64).
Rappe et al. (65) compared the PCDFs occurring in the
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Table 4. Relative levels of PCDFs in livers of Yusho patients.a
Tetrachloro- Pentachloro-
Ibtal PCDF dibenzofurans, ppm dibenzofurans, ppm Hexachlorodibenzo-
Time of death content, ppm 2,3,6,8- 2,3,7,8- 1,2,4,7,8- 2,3,4,7,8- furans, ppm
July 1969 17.6 4.0 1.7 40.3 39.2 14.8
July 1969 2.0 4.0 1.0 60.0 20.0 15.0
May 1972 0.45 6.7 trc 20.0 66.7 6.7
March 1977 0.16 NDb ND 12.5 62.5 25.0
aProm Kuroki and Masuda (66).
bND = not detected.
ctr = trace.
toxic rice oil with those present in the livers of two
Yusho patients. They observed that isomers with ad-
jacent unsubstituted carbon atoms which were present
in the oil were not detectable in the patients. Isomers
such as 2,3,6,8- and 2,3,7,8-tetrachlorodibenzofuran,
1,2,4,7,8- and 2,3,4,7,8-pentachlorodibenzofuran and
1,2,4,6,7,8-, 1,2,3,4,7,8-, 1,2,3,6,7,8- and 2,3,4,6,7,8-
hexachlorodibenzofuran were detected at equal or higher
levels in the patients than in the Yusho oil. One might
expect that these isomers would be resistant to metab-
olism. The presence of 1,2,3,4,6,7,8-heptachlorodiben-
zofuran in the oil but not in the patients might suggest
that this highly chlorinated isomer was not well ab-
sorbed. Exposed patients who died shortly after the
poisoning occurred had higher total levels of PCDFs
and relatively higher amounts of the tetrachlorodiben-
zofuran isomers than those who died 9 years after ex-
posure (Table 4). However, the relative content ofthe
toxic isomer, 2,3,4,7,8-pentachlorodibenzofuran, was
notedtoincreasewithtime (66). Achangeintherelative
isomeric composition ofPCDFs in commercial products
such as pentachlorophenols as compared to biological
samples also exists in fat samples taken from turtles
and seals (67).
The metabolism of PCDFs has not yet been studied
in great detail. Mono- and dihydroxy derivatives were
detected as metabolites from rats given 2-chloro-, 2,8-
dichloro-, and 2,3,8-trichlorodibenzofuran (61). In a se-
ries ofstudies from this laboratory (20,21,30,68), it was
reported that 2,3,7,8-tetrachlorodibenzofuran was me-
tabolized and excreted by rats, mice, and monkeys, while
it persisted in the guinea pig. At least four metabolites
were detected but have not yet been characterized (57).
An examination of the fate of pure 1,2,4,6,7,9-hexa-
chlorodibenzofuran (HCDF) as compared to a prepa-
ration containing approximately 35% pentachloro-
dibenzofuran contaminants suggested that the HCDF
was not readily metabolized, while the pentachloro con-
taminants were metabolized and excreted (Birnbaum,
unpublished observations). Using a mixture ofPCDFs,
Kuroki and co-workers (69) showed that both rats and
monkeys excreted 1,2,7,8- and 2,3,7,8-tetrachlorodi-
benzofuran and 1,2,3,7,8- and 1,2,4,7,8-pentachloro-
dibenzofuran, while 2,3,4,7,8-pentachlorodibenzofuran
and hexachlorodibenzofuran were retained. In fact, the
toxic 2,3,4,7,8-pentachlorodibenzofuran isomer was
concentrated and retained in the liver ofboth rats and
monkeys, a situation similar to the observed retention
of this isomer in Yusho victims (66) (Table 4).
More extensive metabolite characteriation has cen-
tered on the highly toxic compound, 2,3,7,8-tetrachlo-
rodibenzodioxin. The lower chlorinated isomers are
metabolized to hydroxylated derivatives (70). Although
early in vivo studies with TCDD failed to reveal the
presence of metabolites, it is now clear that TCDD is
metabolized at a finite rate. TCDD metabolites have
been detected from rats (71) mice (42) and hamsters
(41,72). The primary in vivo metabolic products ofTCDD
seem to be phenols. Using rat heptocytes, Sawahata et
al. (73) were able to generate at least two metabolites
of TCDD which were identified as 1-hydroxy-2,3,7,8-
TCDD and 8-hydroxy-2,3,7-trichlorodibenzo-p-dioxin.
Poiger et al. (74) were able to identify five phenolic
metabolites produced in vivo by dogs. Dogs seem to
have more ability to metabolize TCDD than do many
other species, a situation reminiscent of that with
2,4,5,2',4',5'-hexachlorobiphenyl.
Although metabolism is in general a prerequisite for
excretion of these highly lipophilic compounds, excep-
tions do exist. Unchanged TCDD could be detected in
the feces of TCDD-treated hamsters (7). Similarly,
TCDF could be detected in the feces of TCDF-treated
guinea pigs (21). Whether this was due to transluminal
passage or action of microbial flora has not yet been
resolved.
In general, the molecular weight is a major deter-
minant ofthe route of excretion (75). Compounds with
a molecular weight ofless than 300 tend to be excreted
primarily in the urine while those with molecular weights
greaterthan500are excreted viathebiliary-fecalroute.
However, this molecular weight cut-off tends to vary
with species, with mice and rats tending to have com-
pounds appearing in the feces which would be in the
urine ofmonkeys and dogs. Mainly metabolites are de-
tected in urine and bile, but appreciable amounts of
parent chemical may appear in the feces, as mentioned
for TCDD, TCDF, and 2,4,5,2',4',5'- hexachlorobi-
phenyl, suggesting the occurrence of passive diffusion
into the gastrointestinal tract. Lactation can also serve
as a route of excretion.
The elimination kinetics ofPCB, PCDD, PCDF, PCN
and other halogenated derivatives tend to follow first-
order processes. In general, except as modified by var-
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Table 5. Half-lives for elimination.
t112 for excretion,
daysb
30
31
11
24
11
Octachlorodibenzo-p-dioxin
TCDF
17.9
2.1
31.4
6.5
2.8
5.4
HCDF 13.0
1,2-Dichloronaphthalene 1.2
21 Rat
40 Guinea pig
2 Rat
2 Mouse (B6)
4 Mouse (D2)
8 Monkey
8 Rat
1 Rat
nexabromonapntnalene 104.2
2,4,5,2',4',5'-PBB
4-Chlorobiphenyl
66
0.7
0.9
4,4'-Dichlorobiphenyl 6.7
0.2
1.9
0.7
2,5,4'-Trichlorobiphenyl
2,4,5,2',5'-Pentachlorobiphenyl
2,3,6,2',3',6'-Hexachlorobiphenyl
2,4,5,2',4',5'-Hexachlorobiphenyl
3.7
7.4
12.2
35.3
4.0
3.7
160.0
21
17
141.9
2.5
5 Rat
2 Rat
1 Rat
1 Mouse
1 Dog
19 Monkey
01 1 Rat
1 Mouse
3 Rat
2 Rat
2 Rat
1 Mouse
1 Dog
7 Monkey
1 Rat
8 Dog
00 Monkey
00 Rat
Xo Mouse
4-Iodobiphenyl 1.4 1 Rat
aRatio of percent of the total dose excreted in feces to the percent of the total dose excreted in urine.
bMeasure of the time required to eliminate 50% of the dose.
iations inbody composition, i.e., adipose tissue content,
the rates of elimination of halogenated aromatics tend
tobedirectlyrelated totheirrates ofmetabolism. Table
5 gives the relative half-lives for elimination of the
chemical from the body and the ratio of excretion in
feces to that in urine for many of the compounds dis-
cussedinthisreview. Notonlyis the effect ofincreasing
size on the route of excretion apparent, but as the re-
sistance to metabolism increases, so does the relative
amount excreted in the feces, reflecting again the dif-
fusion ofunaltered compounds into the gastrointestinal
tractandhenceintothefeces. The presence ofthelarger
fecal route ofexcretion, probably due both to increased
molecular weight and enhanced lipophilicity.
As mentioned, however, most of the material ap-
pearing in the feces represents metabolites produced
by the liver being excreted via the bile into the small
intestines. Forthe more highly substituted compounds,
enterohepatic circulation does not appear to play a ma-
jor role. However, the interruption of enterohepatic
cycling by treatment of mineral oil or chlorostyramine
has been shown to enhance elimination of2,4,5,2',4',5'-
hexabromobiphenyl in monkeys (80). Such treatment
would not only prevent reabsorption of biliary metab-
olites but oflipophilic parentcompound. Mineral oil would
Chemical
TCDD
Feces/urinea
15.7
>99
2.7
1.2
1.4
Species
Guinea pig
Rat
Mouse (B6)
Mouse (D2)
Hamster
Reference
(20)
(76)
(42)
(42)
(41)
(22)
(21,77)
(19)
(20)
(20)
(68)
Birnbaum,
unpublished
(23)
(24)
(18)
(17)
(78)
(39)
(39)
(17)
(78)
(53)
(17)
(17)
(78)
(79)
(79)
(37)
(54)
(54)
(17)
(78)
(11)
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also enhance passive diffusion into the gutbyincreasing
the hydrophobicity of gut contents.
The basic structural features governing the disposi-
tion of halogenated aromatic hydrocarbons have been
known for several years. The size and electronegativity
ofthe halogen, the numbers of halogens, and their po-
sition all play a role in determining the physical and
biochemicalproperties ofthecompound inquestion. The
nature of the ring structure also has a role. Generali-
zationsthatlipophilicityofcompoundsfavorsabsorption
and distribution while adjacent unsubstituted carbon
atoms predispose towards metabolism and thence ex-
cretion seem pertinent. However. the brominated de-
rivatives do seem to be more lipophilic than their
chlorinated analogs resulting in such a degree ofinsol-
ubility that absorption is impeded. A similar situation
seems to exist for the completely substituted dioxins,
naphthalenes, and furans which may neverbe absorbed
and are therefore low in toxicity.
The presence ofthe ether linkage in dioxins and fur-
ans may enhance their metabolism relative to the bi-
phenyls. The strained ether bond in the furans may
explain their ease of oxidation relative to the sym-
metrical situation which exists inthe dioxins. However,
the great species variations observed in metabolism is
still unclear, as in the position that humans occupy in
both the toxic sensitivity disposition picture relative to
other species.
Pharmacokinetic modeling may be helpful in this re-
gard. Physiological pharmacokinetic models for several
PCB isomers have been developed in the rat (81) and
mouse (82), for 2,4,5,2',4',5'-PBB in the rat (83), and
for2,3,7,8-TCDF in rats, mice and monkeys (84). These
studies demonstrate the equilibrium relationship that
exists between blood and other tissues, and that ifthe
uptake, accumulation and disposition parameters are
known, one can predict the overall distribution. The
physiological models derived from rats for PCBs have
been successfully applied tothemouse, ashavethe data
for a single TCDF isomer been shown to be applicable
to other species. The major limitation to extrapolation
ofpharmacokinetic dataisthe factthatmetabolism var-
ies between species (4). Further measurements ofmet-
abolic capabilities are required to be able to improve
predictions of species disposition as well as the effects
thatstructureplaysonthedisposition ofthisentireclass
of compounds.
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